vTv Therap(VTVT.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
vTv Therap
VTVT.US
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd.
1.820 T
VTVT.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
BiotechnologyIndustry
Industry Ranking50/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.60%C
    • Profit Margin6.11%B
    • Gross Margin75.63%A
  • Growth ScoreA
    • Revenue YoY216600.00%A
    • Net Profit YoY112.05%A
    • Total Assets YoY208.53%A
    • Net Assets YoY911.12%A
  • Cash ScoreC
    • Cash Flow Margin-462.43%E
    • OCF YoY216600.00%A
  • Operating ScoreC
    • Turnover0.56C
  • Debt ScoreA
    • Gearing Ratio8.96%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    vTv Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

    benzinga_article·
    US
    VTVT
    +2.82%
    US
    PBE
    +0.11%
    US
    IBB
    +0.10%
    benzinga_article·
    US
    VTVT
    +2.82%
    US
    PBE
    +0.11%
    US
    IBB
    +0.10%

    Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

    PR Newswire·
    US
    VTVT
    +2.82%
    US
    TVTX
    -1.47%
    US
    RTSL
    0.00%
    PR Newswire·
    US
    VTVT
    +2.82%
    US
    TVTX
    -1.47%
    US
    RTSL
    0.00%

    vTv Therapeutics (VTVT) Projected to Post Earnings on Wednesday

    Market Beat·
    US
    VTVT
    +2.82%
    Market Beat·
    US
    VTVT
    +2.82%

    09:26 ETVector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery

    prnewswire·
    US
    VTVT
    +2.82%
    US
    PBE
    +0.11%
    US
    XBI
    -0.69%
    prnewswire·
    US
    VTVT
    +2.82%
    US
    PBE
    +0.11%
    US
    XBI
    -0.69%
    © 2026 Longbridge｜Disclaimer